Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
There is real need to change how we do some of our clinical trials, as currently the testing and development process is too slow, too costly and too failure-prone often we find that a new treatment is no better than the current standard. Much of the focus on the development and testing pathway has been in improving the design of phase I and II trials. In this article, we present examples of new methods for improving the design of phase III trials (and the necessary lead up to them) as they are the most time-consuming and expensive part of the pathway. Key to all these methods is the aim to test many treatments and/or pose many therapeutic questions within one protocol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“In 2010, 5 years into STAMPEDE recruitment, the drug abiraterone was showing very promising results in patients with prostate cancer at more advanced stages than those entering STAMPEDE – that is, in patients with hormone refractory disease.(15) At this time, there were three realistic options: (a) choose to not test…”
BackgroundAbiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801 · cited 4×
“Results from this comparison have recently been presented and have shown that adding abiraterone improves overall survival, the second positive result to emerge from STAMPEDE.(16) The clear success of adding the abiraterone arm subsequently led to the incorporation of three additional research arms into STAMPEDE (Figu…”
BackgroundInfluentialSelf-citationRothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984 · cited 1×
“Individuals taking aspirin who did develop cancer were less likely to have metastases at diagnosis and less likely to develop them subsequently.(25) This body of evidence has led to the development of the Add-Aspirin trial – a basket protocol encompassing four individually powered, randomised, double-blind, phase III…”
BackgroundMore multiarm randomised trials of superiority are needed
Parmar, M. K. B., Carpenter, J., & Sydes, M. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61122-3 · Cited by 127
Self-citationJames, N. D., Sydes, M. R., Mason, M. D., Clarke, N. W., Anderson, J., Dearnaley, D. P., Dwyer, J., Jovic, G., Ritchie, A. W., Russell, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70088-8 · Cited by 123 · cited 2×
“Randomisation to two of the research arms, both of those containing celecoxib, was stopped on the advice of the Independent Data Monitoring Committee at the second interim activity analysis in April 2011, and data supporting this decision were published.(12) The other three research arms successfully recruited past al…”
Trial unpredictability yields predictable therapy gains
Djulbegovic, B., Kumar, A., Glasziou, P., Miladinovic, B., & Chalmers, I. (2013) · Nature · doi:10.1038/500395a · Cited by 66
Cited by
Park, J. J. H., Siden, E., Zoratti, M. J., Dron, L., Harari, O., Singer, J., Lester, R. T., Thorlund, K., & Mills, E. J. (2019) · Trials · doi:10.1186/s13063-019-3664-1 · Cited by 441
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
An overview of precision oncology basket and umbrella trials for clinicians
Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K., & Mills, E. J. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21600 · Cited by 233
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
Self-citationCarhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211008567 · Cited by 51
Metadata
- Authors
- Parmar, M. K., Sydes, M. R., Cafferty, F. H., Choodari-Oskooei, B., Langley, R. E., Brown, L., Phillips, P. P., Spears, M. R., Rowley, S., Kaplan, R., James, N. D., Maughan, T., Paton, N., & Royston, P. J.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2017-08-22
- Volume
- 14
- Issue
- 5
- Pages
- 451-461
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2753465099
- Cited by
- 91
- References
- 6
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. https://app.cochat.ai/papers/10.1177/1740774517725697
- The paper
- Parmar, M. K., Sydes, M. R., Cafferty, F. H., Choodari-Oskooei, B., Langley, R. E., Brown, L., Phillips, P. P., Spears, M. R., Rowley, S., Kaplan, R., James, N. D., Maughan, T., Paton, N., & Royston, P. J. (2017). Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials. https://doi.org/10.1177/1740774517725697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.